These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27371933)

  • 1. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
    Dong K; Wang X; Yang X; Zhu X
    J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.
    Wang W; Cao X; Zhu X; Gu Y
    J Mol Model; 2013 Jun; 19(6):2635-45. PubMed ID: 23525963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding Mechanism of Inhibitors to CDK5/p25 Complex: Free Energy Calculation and Ranking Aggregation Analysis.
    Wu Q; Kang H; Tian C; Huang Q; Zhu R
    Mol Inform; 2013 Mar; 32(3):251-60. PubMed ID: 27481520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.
    Zhang B; Tan VB; Lim KM; Tay TE; Zhuang S
    J Mol Model; 2007 Jan; 13(1):79-89. PubMed ID: 16770643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
    Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
    Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
    Rath SL; Senapati S
    PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
    Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
    J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
    Shukla R; Singh TR
    J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
    Otyepka M; Bártová I; Kríz Z; Koca J
    J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4.
    Gu Y; Wang W; Zhu X; Dong K
    J Mol Model; 2014 Feb; 20(2):2075. PubMed ID: 24481594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors.
    Xie H; Li Y; Yu F; Xie X; Qiu K; Fu J
    Int J Mol Sci; 2015 Nov; 16(11):27350-61. PubMed ID: 26580609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
    Zhou H; Wang C; Ye J; Chen H; Tao R
    Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
    Zhou H; Wang C; Deng T; Tao R; Li W
    J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
    Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
    Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
    Wang X; Pan P; Li Y; Li D; Hou T
    Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
    Nair N; Kudo W; Smith MA; Abrol R; Goddard WA; Reddy VP
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3957-61. PubMed ID: 21641213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.